Pharmacokinetics of diazepam in disordered liver function.
The plasma elimination curves of diazepam following intravenous administration of 10 mg were studied in nine patients with cirrhosis of the liver and four patients without liver disease. The data were analyzed according to a two compartment model. The mean biological half-life (T/2) of diazepam was increased five-fold in patients with cirrhosis compared to the controls (164 hours vs. 32.1 hours). The plasma clearance of diazepam could be correlated neither with a quantitative measure of liver function, as estimated by galactose elimination capacity, nor to semiquantitative measures of liver function, such as serum albumin and prothrombin. It is suggested that the plasma clearance of diazepam is an inaccurate index of its rate of hepatic metabolism due to the complex kinetics of the drug.
D000328:Adult; D000368:Aged; D002849:Chromatography, Gas; D003975:Diazepam / Q000008:administration & dosage / Q000097:blood*; D005260:Female; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D008103:Liver Cirrhosis / Q000097:blood*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged
D003975:Diazepam